Skip to content

Nuvectis Pharma, Inc. NVCT Other current assets

Other current assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.6B-16.9%
Pfizer logo
PfizerPFE
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Eli Lilly logo
Eli LillyLLY
NeoGenomics logo
NeoGenomicsNEO

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s other current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s other current assets?
Nuvectis Pharma, Inc. (NVCT) reported other current assets of $268K in Q1 2026.
How has Nuvectis Pharma, Inc.'s other current assets changed year-over-year?
Nuvectis Pharma, Inc.'s other current assets decreased by 5.6% year-over-year, from $284K to $268K.
What is the long-term trend for Nuvectis Pharma, Inc.'s other current assets?
Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s other current assets has grown at a -4.7% compound annual growth rate (CAGR), from $91K to $75K.